

15 October 2007

Peter House
Oxford Street
Manchester
M1 5AN

Tel: 0161 209 3855
Fax: 0161 209 3889
Email: nice@nice.org.uk
www.nice.org.uk

Via Email

Single Technology Appraisal

**Cetuximab for Locally Advanced Squamous Cell Cancer
of the Head and Neck**

Dear Consultee, Commentator and Experts,

With reference to the decision of the Appeal Panel on the appraisal of cetuximab for the treatment of patients with locally advanced squamous cell cancer of the head and neck (sent to you on 2 October 2007) the Institute is seeking further information to inform future deliberations of the Appraisal Committee.

Specifically, the Institute is seeking your help in highlighting to the Appraisal Committee information that relates to the efficacy of carboplatin alone, and to the safety or toxicity of carboplatin plus fluorouracil, in patients with locally advanced squamous cell cancer of the head and neck.

Your information is gladly received at the earliest available opportunity but no later than **Monday 12 November 2007 at 5pm**.

Please submit your response via email to Christopher Feinmann, Project Manager on christopher.feinmann@nice.org.uk. If you have any technical queries, please contact Ms Nicola Hay, Technical Analyst, on nicola.hay@nice.org.uk.

Yours sincerely

Meindert Boysen, Associate Director STA
Centre for Health Technology Evaluation